

Chuck Grassley

AMENDMENT NO. _____ Calendar No. _____

Purpose: To modify the definition of the term “hemp” and to require the Attorney General to make a determination as to whether cannabidiol should be a controlled substance and listed in a schedule under the Controlled Substances Act and to expand research on the cannabidiol and marihuana.

IN THE SENATE OF THE UNITED STATES—115th Cong., 2d Sess.

S. _____

To provide for the reform and continuation of agricultural and other programs of the Department of Agriculture through fiscal year 2023, and for other purposes.

Referred to the Committee on _____ and ordered to be printed

Ordered to lie on the table and to be printed

AMENDMENTS intended to be proposed by _____

Viz:

- 1 Beginning on page 803, strike line 23 and all that
- 2 follows through page 804, line 4, and insert the following:
- 3 “(1) HEMP.—The term ‘hemp’—
- 4 “(A) means the plant *Cannabis sativa* L.
- 5 and any part of that plant, whether growing or
- 6 not, with a delta-9 tetrahydrocannabinol con-
- 7 centration of not more than 0.3 percent on a
- 8 dry weight basis; and

1 “(B) does not include the derivatives, ex-
2 tracts, cannabinoids, isomers, acids, salts, and
3 or salts of isomers, whether growing or not, of
4 the *Cannabis sativa* L.

5 At the end, add the following:

6 **TITLE XIII—CANNABIDIOL AND**
7 **MARIJUANA RESEARCH EX-**
8 **PANSION ACT**

9 **SEC. 13001. SHORT TITLE.**

10 This title may be cited as the “Cannabidiol and Mari-
11 juana Research Expansion Act”.

12 **Subtitle A—Registrations for**
13 **Marihuana Research**

14 **SEC. 13101. MARIHUANA RESEARCH APPLICATIONS.**

15 Section 303(f) of the Controlled Substances Act (21
16 U.S.C. 823(f)) is amended—

17 (1) by redesignating paragraphs (1) through

18 (5) as subparagraphs (A) through (E), respectively;

19 (2) by striking “(f) The Attorney General” and
20 inserting “(f)(1) The Attorney General”;

21 (3) by striking “Registration applications” and
22 inserting the following:

23 “(2) Registration applications”;

1 (4) by striking “Article 7” and inserting the
2 following:

3 “(4) Article 7”; and

4 (5) by inserting before paragraph (4), as so
5 designated, the following:

6 “(3)(A) The Attorney General shall register a
7 practitioner to conduct research with marihuana if—

8 “(i) the applicant’s research protocol—

9 “(I) has been reviewed and allowed—

10 “(aa) by the Secretary under sec-
11 tion 505(i) of the Federal Food,
12 Drug, and Cosmetic Act (21 U.S.C.
13 355(i));

14 “(bb) by the National Institutes
15 of Health or another Federal agency
16 that funds scientific research; or

17 “(cc) pursuant to section
18 1301.18 of title 21, Code of Federal
19 Regulations, or any successor thereto;

20 “(ii) the applicant has demonstrated that
21 there are effective procedures in place to ade-
22 quately safeguard against diversion of the con-
23 trolled substance for legitimate medical or sci-
24 entific use pursuant to section 13104 of the

1 Cannabidiol and Marijuana Research Expansion
2 Act.

3 “(B) The Attorney General shall approve an
4 application for registration under this paragraph un-
5 less the Attorney General determines that the
6 issuance of the registration would be inconsistent
7 with the public interest. In determining the public
8 interest, the following factors shall be considered:

9 “(i) The applicant’s experience in dis-
10 pensing, or conducting research with respect to,
11 controlled substances.

12 “(ii) The applicant’s conviction record
13 under Federal or State laws relating to the
14 manufacture, distribution, or dispensing of con-
15 trolled substances.

16 “(iii) Compliance with applicable State,
17 Federal, or local laws relating to controlled sub-
18 stances.

19 “(iv) Such other conduct by the applicant
20 that may threaten the public health and safety.

21 “(C)(i) Not later than 60 days after the date on
22 which the Attorney General receives a complete ap-
23 plication for registration under this paragraph, the
24 Attorney General shall—

25 “(I) approve the application; or

1 “(II) request supplemental information.

2 “(ii) For purposes of clause (i), an application
3 shall be deemed complete when the applicant has
4 submitted documentation showing that the require-
5 ments under subparagraph (A) are satisfied.

6 “(D) Not later than 30 days after the date on which
7 the Attorney General receives supplemental information as
8 described in subparagraph (C)(i)(II) in connection with an
9 application described in this paragraph, the Attorney Gen-
10 eral shall approve or deny the application.

11 “(E) If an application described in this paragraph is
12 denied, the Attorney General shall provide a written expla-
13 nation of the basis of denial to the applicant.”.

14 **SEC. 13102. RESEARCH PROTOCOLS.**

15 (a) **IN GENERAL.**—The Attorney General shall
16 amend section 1301.18 of title 21, Code of Federal Regu-
17 lations (as in effect on the date of enactment of this Act)
18 by striking subsections (c) and (d) and inserting the fol-
19 lowing:

20 “(c) In the event that the registrant desires to in-
21 crease the quantity of a controlled substance used for an
22 approved research project, he/she shall submit a request
23 to the Registration Unit, Drug Enforcement Administra-
24 tion, by registered mail, return receipt requested. See the
25 Table of DEA Mailing Addresses in 1321.01 of this chap-

1 ter for the current mailing address. The request shall con-
2 tain the following information: DEA registration number;
3 name of the controlled substance or substances and the
4 quantity of each authorized in the approved protocol; and
5 the additional quantity of each desired. Upon return of
6 the receipt, the registrant shall be authorized to purchase
7 and use the additional quantity of the controlled substance
8 or substances specified in the request.

9 “(d) In the event the registrant desires to conduct
10 research beyond the variations provided in the registrant’s
11 approved protocol (excluding any increase in the quantity
12 of the controlled substance requested for his/her research
13 project as outlined in subsection (c) of this section), he/
14 she shall submit 3 copies by registered mail, with a return
15 receipt requested, and a copy through the online process
16 established by the Registration Unit, Drug Enforcement
17 Administration of a supplemental protocol in accordance
18 with subsection (a) of this section describing the new re-
19 search and omitting information in the supplemental pro-
20 tocol which has been stated in the original protocol. Unless
21 explicitly denied, supplemental protocols shall be consid-
22 ered approved 30 days after the date on which the return
23 receipt is returned.”.

24 (b) LIMITATION ON MODIFICATION OF PROTO-
25 COLS.—The Attorney General may not amend section

1 1301.18 of title 21, Code of Federal Regulations, as
2 amended by the Attorney General pursuant to subsection
3 (a) of this section, or promulgate any other regulation, in
4 a manner that further restricts the ability of a registrant
5 to increase the quantity of a controlled substance used for
6 an approved research project or conduct research beyond
7 the variations provided in the registrant's approved pro-
8 tocol.

9 **SEC. 13103. APPLICATIONS TO MANUFACTURE MARIHUANA**
10 **FOR RESEARCH.**

11 (a) IN GENERAL.—Section 303 of the Controlled
12 Substances Act (21 U.S.C. 823) is amended—

13 (1) by redesignating subsections (e) through (k)
14 as subsections (d) through (l), respectively;

15 (2) by inserting after subsection (b) the fol-
16 lowing:

17 “(c)(1)(A) As it relates to applications to manufac-
18 ture marijuana for research purposes, if the Attorney Gen-
19 eral places a notice in the Federal Register to increase
20 the number of entities registered under this Act to manu-
21 facture marijuana to supply legitimate researchers in the
22 United States, the Attorney General shall, not later than
23 60 days after the date on which the Attorney General re-
24 ceives a completed application—

25 “(i) approve the application; or

1 “(ii) request supplemental information.

2 “(B) For purposes of subparagraph (A), an applica-
3 tion shall be deemed complete when the applicant has sub-
4 mitted documentation showing that the requirements des-
5 ignated in the notice in the Federal Register are satisfied.

6 “(C) Not later than 30 days after the date on which
7 the Attorney General receives supplemental information
8 requested under subparagraph (A)(ii) with respect to an
9 application, the Attorney General shall approve or deny
10 the application.

11 “(2) In determining whether to approve an applica-
12 tion described in paragraph (1), the Attorney General
13 shall consider the demand from researchers for an ade-
14 quate and uninterrupted supply of specific strains of mari-
15 juana and for marijuana grown to specific manufacturing
16 processes.

17 “(3) If an application described in this subsection is
18 denied, the Attorney General shall provide a written expla-
19 nation of the basis of denial to the applicant.”;

20 (3) in subsection (h)(2), as so redesignated, by
21 striking “subsection (f)” each place it appears and
22 inserting “subsection (g)”;

23 (4) in subsection (j)(1), as so redesignated, by
24 striking “subsection (d)” and inserting “subsection
25 (e)”; and

1 (5) in subsection (k), as so redesignated, by
2 striking “subsection (f)” each place it appears and
3 inserting “subsection (g)”.

4 (b) TECHNICAL AND CONFORMING AMENDMENTS.—

5 (1) The Controlled Substances Act (21 U.S.C.
6 801 et seq.) is amended—

7 (A) in section 102 (21 U.S.C. 802)—

8 (i) in paragraph (52)(B)—

9 (I) by striking “303(f)” each
10 place it appears and inserting
11 “303(g)”; and

12 (II) in clause (i), by striking
13 “(d), or (e)” and inserting “(e), or
14 (f)”; and

15 (ii) in paragraph (54), by striking
16 “303(f)” each place it appears and insert-
17 ing “303(g)”;

18 (B) in section 304 (21 U.S.C. 824), by
19 striking “303(g)(1)” each place it appears and
20 inserting “303(h)(1)”;

21 (C) in section 307(d)(2) (21 U.S.C.
22 827(d)(2)), by striking “303(f)” and inserting
23 “303(g)”;

1 (D) in section 311(h) (21 U.S.C. 831(h)),
2 by striking “303(f)” each place it appears and
3 inserting “303(g)”;

4 (E) in section 401(h)(2) (21 U.S.C.
5 841(h)(2)), by striking “303(f)” each place it
6 appears and inserting “303(g)”;

7 (F) in section 403(e)(2)(B) (21 U.S.C.
8 843(e)(2)(B)), by striking “303(f)” and insert-
9 ing “303(g)”;

10 (G) in section 512(c)(1) (21 U.S.C.
11 882(e)(1)) by striking “303(f)” and inserting
12 “303(g)”.

13 (2) Section 1008(e) of the Controlled Sub-
14 stances Import and Export Act (21 U.S.C. 958(e))
15 is amended—

16 (A) in paragraph (1), by striking “303(d)”
17 and inserting “303(e)”;

18 (B) in paragraph (2)(B), by striking
19 “303(h)” and inserting “303(i)”.

20 (3) Title V of the Public Health Service Act (42
21 U.S.C. 290aa et seq.) is amended—

22 (A) in section 520E-4(c) (42 U.S.C.
23 290bb-36d(e)), by striking “303(g)(2)(B)” and
24 inserting “303(h)(2)(B)”;

1 (B) in section 544(a)(3) (42 U.S.C.
2 290dd-3(a)(3)), by striking “303(g)” and in-
3 serting “303(h)”.

4 **SEC. 13104. SECURITY REQUIREMENTS.**

5 (a) IN GENERAL.—An individual or entity engaged
6 in researching marijuana or its components shall store it
7 in a securely locked, substantially constructed cabinet.

8 (b) REQUIREMENTS FOR OTHER MEASURES.—Any
9 other security measures required by the Attorney General
10 to safeguard against diversion shall be consistent with
11 those required for practitioners conducting research on
12 other controlled substances in schedules I and II in section
13 202(c) of the Controlled Substances Act (21 U.S.C.
14 812(c)) that have a similar risk of diversion and abuse.

15 **SEC. 13105. PROHIBITION AGAINST REINSTATING INTER-**
16 **DISCIPLINARY REVIEW PROCESS FOR NON-**
17 **NIH FUNDED RESEARCHERS.**

18 The Secretary of Health and Human Services may
19 not—

20 (1) reinstate the Public Health Service inter-
21 disciplinary review process described in the guidance
22 entitled “Guidance on Procedures for the Provision
23 of Marijuana for Medical Research” (issued on May
24 21, 1999); or

1 (2) require another review of scientific protocols
2 that is applicable only to research on marijuana or
3 its components.

4 **Subtitle B—Proceedings for Con-**
5 **trol, Transfer, or Removal of**
6 **Cannabidiol**

7 **SEC. 13201. SCIENTIFIC AND MEDICAL EVALUATIONS.**

8 Not later than 1 year after the date of enactment
9 of this Act, the Attorney General and the Secretary of
10 Health and Human Services shall each complete the sci-
11 entific and medical evaluation described in section 201(b)
12 of the Controlled Substances Act (21 U.S.C. 811(b)) as
13 to cannabidiol, which shall take into consideration the fac-
14 tors described in paragraphs (1) through (8) of subsection
15 (c) of section 201 of that Act (21 U.S.C. 811(c)).

16 **SEC. 13202. PROCEEDINGS TO CONTROL, TRANSFER, OR RE-**
17 **MOVE CANNABIDIOL.**

18 After taking into consideration the evaluation de-
19 scribed in subsection (a) of section 13201, if the Attorney
20 General determines that the evaluations, recommenda-
21 tions, and all other relevant data warrant control, trans-
22 fer, or removal of cannabidiol, the Attorney General shall
23 initiate proceedings for control, transfer, or removal under
24 section 201(a) of the Controlled Substances Act (21
25 U.S.C. 811(a)).

1 **Subtitle C—Development of FDA-**
2 **approved Drugs Using**
3 **Cannabidiol and Marihuana**

4 **SEC. 13301. DEFINITIONS.**

5 In this title—

6 (1) the term “appropriately registered” means
7 that an individual or entity is registered under the
8 Controlled Substances Act (21 U.S.C. 801 et seq.)
9 to engage in the type activity that is carried out by
10 the individual or entity with respect to with a con-
11 trolled substance on the schedule that is applicable
12 to cannabidiol or marihuana, as applicable;

13 (2) the term “cannabidiol” means the
14 nonpsychoactive substance, cannabidiol, as derived
15 from marihuana or the synthetic formulation;

16 (3) the terms “controlled substance”, “dis-
17 pense”, “distribute”, “manufacture”, “marihuana”,
18 and “practitioner” have the meanings given such
19 terms in section 102 of the Controlled Substances
20 Act (21 U.S.C. 802);

21 (4) the term “covered institution of higher edu-
22 cation” means an institution of higher education (as
23 defined in section 101 of the Higher Education Act
24 of 1965 (20 U.S.C. 1001)) that—

1 (A)(i) has highest or higher research activ-
2 ity, as defined by the Carnegie Classification of
3 Institutions of Higher Education; or

4 (ii) is an accredited medical school or an
5 accredited school of osteopathic medicine; and

6 (B) is appropriately registered under the
7 Controlled Substances Act (21 U.S.C. 801 et
8 seq.);

9 (5) the term “drug” has the meaning given the
10 term in section 201(g)(1) of the Federal Food Drug
11 and Cosmetics Act (21 U.S.C. 321(g)(1));

12 (6) the term “medical research for drug devel-
13 opment” means medical research that is—

14 (A) a preclinical study or clinical investiga-
15 tion conducted in accordance with section
16 505(i) of the Federal Food, Drug, and Cos-
17 metic Act (21 U.S.C. 355(i)) or otherwise per-
18 mitted by the Department of Health and
19 Human Services to determine the potential
20 medical benefits of marijuana or cannabidiol as
21 a drug; and

22 (B) conducted by a covered institution of
23 higher education, practitioner, or manufacturer
24 that is appropriately registered under the Con-
25 trolled Substances Act (21 U.S.C. 801 et seq.);

1 (7) the term “registered manufacturer” means
2 an individual or entity who is appropriately reg-
3 istered to manufacture controlled substances under
4 the Controlled Substances Act (21 U.S.C. 801 et
5 seq.), including an individual or entity appropriately
6 registered to manufacture controlled substances as
7 part of research; and

8 (8) the term “State” means any State of the
9 United States, the District of Columbia, and any
10 territory of the United States.

11 **SEC. 13302. MEDICAL RESEARCH ON CANNABIDIOL.**

12 (a) **IN GENERAL.**—Notwithstanding any provision of
13 the Controlled Substances Act (21 U.S.C. 801 et seq.),
14 the Safe and Drug-Free Schools and Communities Act (20
15 U.S.C. 7101 et seq.), chapter 81 of title 41, United States
16 Code, or any other Federal law, an appropriately reg-
17 istered covered institution of higher education, a practi-
18 tioner, or a manufacturer may manufacture, distribute,
19 dispense, or possess marijuana or cannabidiol if the mari-
20 huana or cannabidiol is manufactured, distributed, dis-
21 pensed, or possessed, respectively, for purposes of medical
22 research for drug development.

23 (b) **REGISTRATION FOR RESEARCH INVOLVING**
24 **CANNABIDIOL.**—

1 (1) INITIAL PERIOD.—During the period begin-
2 ning on the date of enactment of this Act and end-
3 ing on the date on which the Attorney General
4 makes a determination regarding control of
5 cannabidiol, an individual or entity engaged in med-
6 ical research for drug development may distribute,
7 dispense, or possess cannabidiol for purposes of the
8 medical research for drug development if the indi-
9 vidual or entity is registered under the Controlled
10 Substances Act (21 U.S.C. 801 et seq.) to engage in
11 such activity with a controlled substance in schedule
12 II in section 202(e) of the Controlled Substances Act
13 (21 U.S.C. 812(e)).

14 (2) COMPLETION OF ONGOING RESEARCH.—If,
15 as a result of the determination and proceedings de-
16 scribed in title II, cannabidiol is a controlled sub-
17 stance in schedule I in section 202(c) of the Con-
18 trolled Substances Act (21 U.S.C. 812(c)), an indi-
19 vidual or entity engaged in medical research for
20 drug development may continue to distribute, dis-
21 pense, or possess cannabidiol for purposes of com-
22 pleting the medical research for drug development if
23 the individual or entity—

24 (A) was engaged in the medical research
25 for drug development in accordance with para-

1 graph (1) on or before the date on which the
2 proceedings are completed; and

3 (B) is registered under the Controlled Sub-
4 stances Act (21 U.S.C. 801 et seq.) to engage
5 in such activity with a controlled substance in
6 schedule II in section 202(e) of the Controlled
7 Substances Act (21 U.S.C. 812(e)).

8 **SEC. 13303. REGISTRATION FOR THE COMMERCIAL PRO-**
9 **DUCTION AND DISTRIBUTION OF FOOD AND**
10 **DRUG ADMINISTRATION APPROVED DRUGS.**

11 The Attorney General shall register an applicant to
12 manufacture or distribute cannabidiol or marijuana for
13 the purpose of commercial production of a drug containing
14 or derived from marijuana that is approved by the Sec-
15 retary of Health and Human Services under section 505
16 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
17 355), in accordance with the applicable requirements
18 under subsection (a) or (b) of section 303 of the Con-
19 trolled Substances Act (21 U.S.C. 823).

20 **SEC. 13304. GOOD MANUFACTURING PRACTICES.**

21 Not later than 180 days after the date of enactment
22 of this Act, the Commissioner of Food and Drugs shall
23 develop and publish recommendations for good manufac-
24 turing practices for growing and producing marijuana for
25 medical research for drug development.

1 **SEC. 13305. IMPORTATION OF CANNABIDIOL FOR RE-**
2 **SEARCH PURPOSES.**

3 The Controlled Substances Import and Export Act
4 (21 U.S.C. 951 et seq.) is amended—

5 (1) in section 1002(a) (21 U.S.C. 952(a))—

6 (A) in paragraph (1), by striking “and” at
7 the end;

8 (B) in paragraph (2)(C), by inserting
9 “and” after “uses,”; and

10 (C) inserting before the undesignated mat-
11 ter following paragraph (2)(C) the following:

12 “(3) such amounts of marijuana or cannabidiol
13 as are—

14 “(A) approved for medical research for
15 drug development (as such terms are defined in
16 section 13301 of the Cannabidiol and Mari-
17 juana Research Expansion Act), or

18 “(B) necessary for registered manufactur-
19 ers to manufacture drugs containing marijuana
20 or cannabidiol that have been approved for use
21 by the Commissioner of Food and Drugs under
22 the Federal Food, Drug, and Cosmetic Act (21
23 U.S.C. 301 et seq.),”; and

24 (2) in section 1007 (21 U.S.C. 957), by amend-
25 ing subsection (a) to read as follows:

1 “(a)(1) Except as provided in paragraph (2), no per-
2 son may—

3 “(A) import into the customs territory of the
4 United States from any place outside thereof (but
5 within the United States), or import into the United
6 States from any place outside thereof, any controlled
7 substance or list I chemical, or

8 “(B) export from the United States any con-
9 trolled substance or list I chemical,
10 unless there is in effect with respect to such person
11 a registration issued by the Attorney General under
12 section 1008, or unless such person is exempt from
13 registration under subsection (b).

14 “(2) Paragraph (1) shall not apply to the im-
15 port or export of marijuana or cannabidiol that has
16 been approved for—

17 “(A) medical research for drug develop-
18 ment authorized under section 13302 of the
19 Cannabidiol and Marijuana Research Expansion
20 Act; or

21 “(B) use by registered manufacturers to
22 manufacture drugs containing marijuana or
23 cannabidiol that have been approved for use by
24 the Commissioner of Food and Drugs under the

1 Federal Food, Drug, and Cosmetic Act (21
2 U.S.C. 301 et seq.).”

3 **Subtitle D—Relation to the Single**
4 **Convention on Narcotic Drugs**

5 **SEC. 13401. RELATION TO THE SINGLE CONVENTION ON**
6 **NARCOTIC DRUGS.**

7 (a) **CONSTRUCTIVE POSSESSION AND CONTROL.—**
8 The registration of manufacturers and distributors of
9 marihuana pursuant to this title shall constitute construc-
10 tive possession and control by the Federal Government for
11 the purposes of the obligations under the Single Conven-
12 tion on Narcotic Drugs.

13 (b) **ARTICLE 28.—**Article 28 of the Single Conven-
14 tion on Narcotic Drugs shall not be construed to prohibit,
15 or impose additional restrictions upon, the manufacturing
16 of marihuana that is conducted in accordance with this
17 title.

18 (c) **SINGLE CONVENTION ON NARCOTIC DRUGS DE-**
19 **FINED.—**In this section, the term “Single Convention on
20 Narcotic Drugs” means the Single Convention on Narcotic
21 Drugs, 1961, as amended by the 1972 Protocol amending
22 the Single Convention on Narcotic Drugs, 1961.

23 **Subtitle E—Safe Harbor**

24 **SEC. 13501. DEFINITIONS.**

25 In this subtitle—

1 (1) the term “adult” means an individual who
2 is not less than 18 years of age;

3 (2) the term “child” means an individual who
4 is not more than 17 years of age;

5 (3) the term “intractable epilepsy” means an
6 epileptic seizure disorder for which standard medical
7 treatment—

8 (A) does not prevent or significantly ame-
9 liorate recurring, uncontrollable seizures; or

10 (B) results in harmful side effects; and

11 (4) the term “neurologist” means an allopathic
12 or osteopathic physician board-certified in neurology
13 in good standing and licensed in the State in which
14 the physician practices neurology.

15 **SEC. 13502. SAFE HARBOR.**

16 Notwithstanding the Controlled Substances Act (21
17 U.S.C. 801 et seq.), the Controlled Substances Import and
18 Export Act (21 U.S.C. 951 et seq.), or any other Federal
19 law, it shall not be unlawful for—

20 (1) a legal guardian to possess or transport
21 cannabidiol or any other nonpsychoactive component
22 of marijuana for purposes of dispensing the
23 cannabidiol or other nonpsychoactive component to a
24 child of the legal guardian if—

1 (A) the child has been treated by a neu-
2 rologist for intractable epilepsy for not less than
3 6 months;

4 (B) the child's neurologist attests that
5 other treatment options have not resulted in
6 significant clinical improvement;

7 (C) the child's neurologist attests that he
8 or she has discussed the currently known poten-
9 tial harms and benefits of using cannabidiol or
10 other nonpsychoactive components of mari-
11 huana as a treatment with the child's legal
12 guardian;

13 (D) the child's neurologist attests that he
14 or she will monitor the child for potential ad-
15 verse reactions; and

16 (E) the legal guardian provides docu-
17 mentation for the requirements under subpara-
18 graphs (A), (B), (C), and (D);

19 (2) an adult to possess or transport cannabidiol
20 or any other nonpsychoactive component of mari-
21 huana if—

22 (A) the adult has been treated by a neu-
23 rologist for intractable epilepsy for not less than
24 6 months;

1 (B) the adult's neurologist attests that
2 other treatment options have not resulted in
3 significant clinical improvement;

4 (C) the adult's neurologist attests that he
5 or she has discussed the currently known poten-
6 tial harms and benefits of using cannabidiol or
7 other nonpsychoactive components of mari-
8 huana as a treatment with the adult;

9 (D) the adult's neurologist attests that he
10 or she will monitor the adult for potential ad-
11 verse reactions; and

12 (E) the adult provides documentation for
13 the requirements under subparagraphs (A),
14 (B), (C), and (D); or

15 (3) a State-licensed physician to discuss the
16 currently known potential harms and benefits of
17 cannabidiol or any other nonpsychoactive component
18 of marijuana as a treatment with a patient of the
19 physician, or the legal guardian of the patient if the
20 patient is a child.

21 **SEC. 13503. SUNSET.**

22 This subtitle shall cease to have force or effect on
23 the date that is 4 years after the date of enactment of
24 this Act.

1 **Subtitle F—Federal Research**

2 **SEC. 13601. FEDERAL RESEARCH.**

3 The Secretary of Health and Human Services, either
4 directly or through awarding grants, contracts, or coopera-
5 tive agreements shall expand, intensify, and coordinate the
6 activities of the National Institutes of Health and other
7 relevant Federal agencies to better determine—

8 (1) the potential therapeutic effects of
9 cannabidiol or marijuana on serious medical condi-
10 tions, including intractable epilepsy; and

11 (2) the potential impacts of marijuana, includ-
12 ing—

13 (A) the effect of increasing delta-9-
14 tetrahydrocannabinol levels on the human body;
15 and

16 (B) the effect of various delta-9-
17 tetrahydrocannabinol levels on cognitive abilities
18 that are required to operate motor vehicles or
19 other heavy equipment.